



Anti-Infective Drugs Markets

Published: 2010-OCT-01

Pages: 243

Format: PDF

Price: 11100 EUR (Single User License)

Description

Six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults, according to the World Health Organization (WHO).

Moreover, threatening pandemics such as swine flu (H1N1 influenza A virus) are adding significant pressure to already strained healthcare budgets of governments around the world. This report analyzes the anti-infective drugs market and highlights the existing and developing anti-infectives used to ameliorate infectious diseases' afflictions on humankind.

Anti-infective drugs include: anti-viral therapeutics, antibiotics, anti-fungal agents and prophylactic treatments such as vaccines. Particular attention is paid to the clinical market segment and the pharmaceutical/biotechnology companies involved in anti-infective drugs with specific emphasis on each company's sales focus, product portfolio and R&D pipeline.

To date, the most successful anti-infective drugs target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV). A number of exciting novel anti-viral and antibiotic compounds are currently revolutionizing anti-infective drugs markets, including Truvada and Valtrex, which are anti-HIV and anti-herpes therapies, respectively.

Significant resources are also being dedicated toward hepatitis A (HAV), hepatitis B (HBV) and Staph infections, including MRSA. What's more, this study will examine the existing and developing anti-infective drugs targeted at infectious diseases that continue to devastate developing countries, including: cholera, dengue fever, meningitis, rotavirus, typhoid and yellow fever.

Table of Contents

1. Overview	9
1.1 Statement of Report	9
1.2 Scope of the Report	9
1.3 Methodology	10
1.4 Executive Summary	11
2. Clinical Syndromes and Therapy	20
2.1 Head and Neck	22
2.1.1 Sinusitis	22
2.1.2 Pharyngotonsillitis	23
2.1.3 Deep Neck Infections	23
2.1.4 Otitis Media and Externa	23
2.1.5 Acute Suppurative Thyroiditis	23
2.2 Eye	24
2.2.1 Conjunctivitis	24
2.2.2 Keratitis	24
2.2.3 Iritis	24
2.2.4 Retinitis	25
2.2.5 Endophthalmitis	25
2.3 Skin and Lymph Nodes	25
2.3.1 Complicated Skin and Skin Structure Infections (cSSSI)	25
2.3.2 Lymphadenitis	25
2.4 Respiratory Tract	26
2.4.1 Bronchitis	26
2.4.2 Laryngitis	26
2.4.3 Pneumonia	26

2.4.4	Influenza	28
2.4.5	Avian Bird Flu	29
2.4.6	Swine Flu	29
2.4.7	Respiratory Syncytial Virus	33
2.4.8	Tuberculosis	33
2.5	Heart and Blood Vessels	37
2.5.1	Endocarditis	37
2.5.2	Acute Pericarditis	37
2.5.3	Myocarditis	37
2.5.4	Vascular Infections	38
2.6	Gastrointestinal Tract, Liver and Abdomen	38
2.6.1	Acute Viral Hepatitis	38
2.6.2	Chronic Hepatitis	39
2.6.3	Biliary Tract Infections	40
2.6.4	Pancreatitis	40
2.6.5	Esophageal Infections	41
2.6.6	Gastroenteritis	41
2.6.7	Peritonitis	42
2.7	Genitourinary Tract	43
2.7.1	Urethritis	43
2.7.2	Prostatitis	43
2.7.3	Urinary Tract Infections	44
2.7.4	Pelvic Inflammatory Disease	44
2.7.5	Candiduria	44
2.7.6	Human Papilloma Virus	44
2.8	Nervous System	45
2.8.1	Bacterial Meningitis	45
2.8.2	Viral Encephalitis	46
2.8.3	Reye's Syndrome	46
2.8.4	Myelitis and Peripheral Neuropathy	46
2.9	Musculoskeletal System	46
2.9.1	Osteomyelitis	46
2.9.2	Polyarthritis	47
2.9.3	Bursitis	47
2.9.4	Psoas Abscess	47
2.10	Human Immunodeficiency Virus (HIV) Infection	47
2.11	Blood-borne Infections	53
2.11.1	Malaria	53
2.11.2	West Nile Virus	56
3.	Anti-Infective Drugs Market	58
3.1	FDA Approvals of New Anti-Infective Therapy	60
3.2	Anti-Infective Drugs in Current Pharmaceutical Developmental Programs	68
3.3	Factors Determining Anti-Infective Drug Development	70
3.4	Pharmaceutical R&D Expenditures	70
4.	Description of Anti-Infective Therapeutic Agents	72
4.1	Anti-Bacterials	72
4.1.1	Anti-Bacterial Therapeutic Agents in Current Formulation	75
4.1.1.1	B-lactam Antibiotics	76
4.1.1.2	Fluoroquinolones	77
4.1.1.3	Glycopeptides	78
4.1.1.4	Macrolides	79
4.1.1.5	Oxazolidinones	80
4.1.1.6	Other Classes of Anti-Bacterial Agents	81
4.1.2	Older Classes of Antibiotics	81
4.2	Anti-Virals	82
4.2.1	Overview	82
4.2.2	Anti-Viral Therapy	82
4.2.3	Anti-Viral Market Leaders	83
4.2.4	Principles of Anti-Viral Therapy	83
4.3	Anti-Fungals	89
4.3.1	Overview	89
4.3.2	Major Classes of Anti-Fungal Therapy	89
4.3.3	Anti-Fungal Agent Resistance	90
4.3.4	Anti-Fungal Agent Market Leaders	91
4.4	Vaccines	91
4.4.1	Overview	91
4.4.2	Principles of Vaccine Therapy	93
4.4.3	Vaccine Market Leaders	94
5.	Market for Anti-Infective Drugs and Vaccines	97
5.1	Molecular Diagnostics in Determining Demand	97
6.	Decision-making Activity in the Anti-Infective Drugs Market	101
6.1	Net Present Value in Making Decisions to Develop and Market Antibiotics	102

7. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Anti-Bacterials 104

7.1 Resistance and Antibiotic Usage 107

8. Global Market Analysis of Anti-Infective Drugs 109

8.1 Market Size 109

8.2 Market Share 109

8.3 Market Drivers 111

9. Global Market for Anti-Bacterial Therapies 112

9.1 Amoxicillin 114

9.2 Nafcillin 114

9.3 Ticarcillin 114

9.4 Imipenem 115

9.5 Ceftriaxone 115

9.6 Cefotetan 115

9.7 Dalbavancin 116

9.8 Doripenem 116

10. Global Market for Anti-Fungal Therapies 118

10.1 Amphotericin B 119

10.2 Azoles 119

10.3 Echinocandins 120

10.4 Flucytosine 120

11. Global Market for Anti-Viral Therapies 121

11.1 Antiretroviral Market 121

11.1.1 The Viral Drug Resistance Crisis 121

11.1.2 Emtricitabine 124

11.1.3 CCR5 Receptor Antagonists 125

11.1.4 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 125

11.2 HCV Infections 126

11.2.1 Pegintron Alpha 126

11.2.2 Ribavirin 127

11.2.3 Boceprevir 127

11.3 Acyclovir 127

11.4 Adefovir 127

11.5 Cidofovir 128

11.6 Entecavir 128

11.7 Fomivirsen 128

11.8 Foscarnet 128

11.9 Ganciclovir 128

12. Market, Demographic and Economic Trends 129

12.1 Emerging Trends in Infectious Diseases Worldwide 129

12.2 Global Burden of Infectious Diseases 130

12.3 The AIDS Model 131

12.4 Dead-end Transmission of Zoonotic and Vector-borne Diseases 131

12.5 Environmentally Persistent Organisms 132

12.6 Old Microbes Cause New Diseases 132

12.7 Microbial Agents and Chronic Diseases 132

12.8 Remerging and Resurging Infections 133

12.9 Geographical Spread of Infectious Diseases 133

12.10 Drug-resistant Microbes 134

12.11 Opportunistic Re-emerging Infections 134

12.12 Re-emerging Zoonotic and Vector-borne Diseases 134

12.13 Influenza 134

12.14 Deliberately Emerging Infections 135

12.15 Meeting the Challenge of Emerging Diseases 135

13. Political/Legal Trends 136

13.1 AATF and Legislation 136

13.2 Bioterrorism and Biowarfare 138

14. Technological Trends 139

14.1 Anti-Microbial Discovery in the Post-genomic Era 139

14.1.1 Anti-Bacterial Polypharmacology 139

14.1.2 Topology of Targets 140

14.1.3 Designer Polypharmacology and Designing HIV-Therapies 140

15. Socio-Cultural Trends 141

16. Competitive Landscape 142

16.1 Introduction 142

16.2 Strengths and Weaknesses in Anti-Microbial Drug Discovery-Commercial 143

16.3 Strengths and Weaknesses in Anti-Microbial Drug Discovery-Academic 144

16.4 Regulatory Hurdles 144

16.5 Business Hurdles 145

17. Sales Performance amongst the Leading Players: Detailed Analysis of Leading Anti-Infective Players 149

17.1 GlaxoSmithKline 149

17.1.1 Overview 149

17.1.2 Sales Focus by Drug Class 149

17.1.3 Marketed Product Portfolio 150

17.1.4 R&D Pipeline Analysis 152

17.1.5 Strategic and Growth Analysis 152

17.2 Merck 153

17.2.1 Overview 153

17.2.2 Sales Focus by Drug Class 154

17.2.3 Marketed Product Portfolio 154

17.2.4 R&D Pipeline Analysis 156

17.2.5 Strategic and Growth Analysis 157

17.3 Pfizer 157

17.3.1 Overview 157

17.3.2 Sales Focus by Drug Class 158

17.3.3 Marketed Product Portfolio 158

17.3.4 R&D Pipeline Analysis 160

17.3.5 Strategic and Growth Analysis 161

17.4 Novartis AG 161

17.4.1 Overview 161

17.4.2 Sales Focus by Drug Class 161

17.4.3 Marketed Product Portfolio 162

17.4.4 R&D Pipeline Analysis 163

17.4.5 Strategic and Growth Analysis 163

17.5 Gilead Sciences 164

17.5.1 Overview 164

17.5.2 Sales Focus by Drug Class 164

17.5.3 Marketed Product Portfolio 165

17.5.4 R&D Pipeline Analysis 165

17.5.5 Strategic and Growth Analysis 166

17.6 Abbott 166

17.6.1 Overview 166

17.6.2 Sales Focus by Drug Class 166

17.6.3 Marketed Product Portfolio 167

17.6.4 R&D Pipeline Analysis 167

17.6.5 Strategic and Growth Analysis 168

17.7 Wyeth (Acquired by Pfizer) 168

17.7.1 Overview 168

17.7.2 Sales Focus by Drug Class 168

17.7.3 Marketed Product Portfolio 169

17.7.4 R&D Pipeline Analysis 169

17.7.5 Strategic and Growth Analysis 170

17.8 Sanofi-Aventis 170

17.8.1 Overview 170

17.8.2 Sales Focus by Drug Class 170

17.8.3 Marketed Product Portfolio 171

17.8.4 R&D Pipeline Analysis 172

17.8.5 Strategic and Growth Analysis 172

17.9 Bristol-Myers Squibb 173

17.9.1 Overview 173

17.9.2 Sales Focus by Drug Class 173

17.9.3 Marketed Product Portfolio 173

17.9.4 R&D Pipeline Analysis 173

17.9.5 Strategic and Growth Analysis 174

17.10 Johnson & Johnson 174

17.10.1 Overview 174

17.10.2 Sales Focus by Drug Class 175

17.10.3 Marketed Product Portfolio 175

17.10.4 R&D Pipeline Analysis 175

17.10.5 Strategic and Growth Analysis 176

17.11 Roche Pharma AG 176

17.11.1 Overview 176

17.11.2 Sales Focus by Drug Class 177

17.11.3 Marketed Product Portfolio 177

17.11.4 R&D Pipeline Analysis 177

17.11.5 Strategic and Growth Analysis 177

18. Company Profiles 179

18.1 Abraxis BioScience, Inc. 179

18.2 Acambis (now Sanofi Pasteur) 179

18.3 Achillion Pharmaceuticals, Inc. 179

18.4 Adlyfe, Inc. 180

18.5 Advanced Life Sciences Holdings, Inc. 181

18.6 Affinium Pharmaceuticals 181

18.7 Akonni Biosystems	181
18.8 Alnylam Pharmaceuticals	181
18.9 APP Pharmaceuticals	182
18.10 Aquapharm Biodiscovery	182
18.11 Arbor Vita Corporation	182
18.12 Arpida Ltd. (Now Evolva)	183
18.13 Avexa Ltd.	183
18.14 Basilea Pharmaceutica AG	183
18.15 Baxter International, Inc.	183
18.16 Biophage Pharma, Inc.	184
18.17 CEL-SCI Corporation	184
18.18 Cerexa, Inc. (Subsidiary of Forest Laboratories)	185
18.19 CombiMatrix Corporation	185
18.20 Cubist Pharmaceuticals, Inc.	185
18.21 Daiichi Sankyo Co., Ltd.	186
18.22 Hospira, Inc.	186
18.23 Incyte Corporation	187
18.24 Idenix Pharmaceuticals, Inc.	187
18.25 Medivir AB	188
18.26 Meiji Holdings Co., Ltd.	188
18.27 MerLion Pharma	189
18.28 Mutabilis	189
18.29 NanoBio Corporation	189
18.30 Nanosphere, Inc.	190
18.31 NanoViricides, Inc.	190
18.32 Novabay Pharmaceuticals, Inc.	190
18.33 Obetech, LLC	191
18.34 Optimer Pharmaceuticals, Inc.	191
18.35 Panacos Pharmaceuticals, Inc.	192
18.36 Paratek Pharmaceuticals, Inc.	192
18.37 Pharmasset, Inc.	192
18.38 Pico Pharmaceuticals, Inc.	193
18.39 PolyMedix, Inc.	193
18.40 PowderMed Ltd. (Subsidiary of Pfizer)	193
18.41 Presidio Pharmaceuticals, Inc.	194
18.42 Progenics Pharmaceuticals, Inc.	194
18.43 Protez Pharmaceuticals (a Novartis Subsidiary)	194
18.44 Ribomed Biotechnologies, Inc.	195
18.45 Rib-X Pharmaceuticals, Inc.	195
18.46 Targanta Therapeutics Corporation, Inc. (Acquired by The Medicine Company)	195
18.47 Theravance, Inc.	196
18.48 Trius Therapeutics	196
18.49 Vertex Pharmaceuticals, Inc.	196
18.50 X-GEN Pharmaceuticals, Inc.	197

Appendix 1: FDA Compliance Policies Regarding Approved New Drug and Antibiotic Drug Products 198

Appendix 2: Anti-HCV Drugs in Development 200

Appendix 3: Market for Anti-Infectives in Animal Health 203

Appendix 4: Diagnostics for Infectious Agents 209

INDEX OF FIGURES

Figure 1.1: Leading Causes of Death in the U.S., 1961-2007	12
Figure 1.2: Global Distribution of Anti-Infective Drugs Sales by Geography	15
Figure 2.1: Incidence Rates of Invasive MRSA Infections by Age 20	
Figure 2.2: U.S. Child Death Rate from Preventable Diseases, 2007	22
Figure 2.3: Infection Rate of Serotype 19A by Age Group in the U.S., 1998-2006	27
Figure 2.4: U.S. Hospitalizations for Types of Respiratory Diseases in Children Under 15 Years of Age	27
Figure 2.5: Economic Burden of Select Lung Diseases in the U.S., 2007	28
Figure 2.6: Infection Rate of Invasive Pneumococcal Disease in the U.S., 1998-2007	28
Figure 2.7: Status of H5N1 Avian Influenza, 2009	29
Figure 2.8: Number of Reported and Confirmed Cases of Influenza H1N1 Strain Worldwide, 2009	31
Figure 2.9: Distribution of H1N1 Flu in the U.S., May 22, 2010	32
Figure 2.10: Novel H1N1 Confirmed and Probable Case Rate in the U.S. by Age Group	32
Figure 2.11: Number of Tuberculosis Cases Among U.S.-born and Foreign-born Persons by Year Reported in the U.S., 1993-2009	34
Figure 2.12: Rate of Tuberculosis Cases Among U.S.-born and Foreign-born Persons by Year Reported in the U.S., 1993-2009	34
Figure 2.13: Rate of Tuberculosis Cases by State/Area in the U.S., 2009	35
Figure 2.14: U.S.-born Tuberculosis Cases by Ethnicity, 2008	36
Figure 2.15: Rate of New Hepatitis A, B and C Infections in the U.S., 1982-2007	39
Figure 2.16: Countries Reporting Outbreaks of Cholera, 2007-2009	42
Figure 2.17: U.S. Rates of Sexually-Transmitted Diseases, 1940-2008	43
Figure 2.18: Rate of New Cases and Deaths of Cervical Cancer by Age Group Worldwide, 2008	45
Figure 2.19: Global Trend of HIV Infection, 1991-2008	48
Figure 2.20: Worldwide Percentage of Adults Living with HIV, 1990-2006	48
Figure 2.21: Worldwide Rate of New HIV Cases, 1990-2008	49
Figure 2.22: Percentage of Adult Population in African Countries with HIV, 2007	49

Figure 2.23: Ethnic Distribution of AIDS Patients in the U.S., 2007 51
 Figure 2.24: Ten Best Selling AIDS Drugs in the U.S., 2009 51
 Figure 2.25: U.S. Rates for New HIV Cases, 2008 52
 Figure 2.26: Global Malaria-Endemic Areas in the Eastern Hemisphere 54
 Figure 2.27: Anti-Malarial Vaccine Pipeline, 2009 55
 Figure 2.28: Global Anti-Malarial Drug Pipeline, 2008 56
 Figure 2.29: West Nile Virus Activity in the U.S., 2009 57
 Figure 3.1: Anti-Infective Drugs Market Projections, 2006-2013 58
 Figure 3.2: Leading Companies in Anti-Infectives Market Share, 2008 59
 Figure 3.3: Number of New Anti-Bacterial Agents Approved by the FDA in the U.S., 1983-2008 62
 Figure 3.4: Total Spending on Healthcare in the U.S., 1960-2008 64
 Figure 3.5: Percentage Breakdown of U.S. Healthcare Spending, 2008 65
 Figure 3.6: International per Capita Healthcare Spending by Country, 2008 65
 Figure 3.7: Generic Drug Applications and Approvals in the U.S., 1995-2006 66
 Figure 3.8: Savings Generated by Generic Use in the U.S. by Therapeutic Category, 1999-2008 67
 Figure 3.9: Anti-Bacterial and Anti-HIV New Molecular Entities (NMEs) Approved by the FDA, 1993-2007 70
 Figure 3.10: Cost for New Drugs by Primary Indication, 2007 71
 Figure 4.1: Market Share by Leading Anti-Bacterial Drug Class 73
 Figure 4.2: Anti-Virals in the Marketplace 82
 Figure 4.3: Anti-Virals Market by Indication, Excluding HIV and HCV 83
 Figure 4.4: Anti-Viral Therapeutics Market by Drug Class 84
 Figure 4.5: Global Distribution of the Lack of Childhood Vaccination 92
 Figure 4.6: GAVI Alliance Members 93
 Figure 4.7: Global Vaccines Market, 2008 94
 Figure 4.8: GlaxoSmithKline's Vaccine Pipeline, 2008 95
 Figure 4.9: Vaccine Market by Geographical Area, 2008 95
 Figure 5.1: Global Market for Molecular Diagnostics, 2002-2013 98
 Figure 6.1: Number of Non-elderly Americans without Health Insurance Coverage, 1994-2008 102
 Figure 6.2: Percentage of Non-elderly Americans without Health Insurance Coverage, 1994-2008 102
 Figure 7.1: Global Multidrug Susceptibility in *P. aeruginosa* 106
 Figure 7.2: Global Frequency of Vancomycin-resistant Enterococci, 2006 106
 Figure 7.3: MRSA Trends According to Patient Location, 1998-2005 107
 Figure 9.1: Market for Injectable Anti-Bacterials, 2008 and 2013 113
 Figure 9.2: Market Share for Major Anti-Bacterial Classes, 2008 and 2013 113
 Figure 9.3: Frequency of *S. aureus* in Skin and Soft Tissue Infections 116
 Figure 11.1: Current and Projected Market Size for Injectable Antiretrovirals by Class, 2008 and 2013 121
 Figure 11.2: Market Share for Injectable Antiretrovirals by Drug Class, 2008 122
 Figure 11.3: HCV Market: Growth and Projections by Drug Class, 2008 and 2013 126
 Figure A3.1: Growth in Global Sales of Antibiotic Products in Animal Health, 2005-2012 203
 Figure A4.1: FIND Pipeline for TB Diagnostics 219

INDEX OF TABLES

Table 1.1: Top Ten Causes of Death Worldwide 12
 Table 1.2: Leading Pharmaceutical Companies in the Anti-Infective Market, 2009 16
 Table 2.1: Annual Rates of Global Infectious Diseases 21
 Table 2.2: Drugs in Development for Chronic Hepatitis B, 2010 40
 Table 2.3: Global HIV Statistics, 2008 50
 Table 3.1: Top Selling Anti-Infective Drugs, 2008 59
 Table 3.2: Sales for Leading Companies' Infectious Diseases Segments, 2008 60
 Table 3.3: Current Drug Development Times and Rates by Therapeutic Indication 61
 Table 3.4: Emerging Therapeutic Approaches 61
 Table 3.5: New Drug Approvals in All Categories from FDA, 2000-2009 62
 Table 3.6: Top Ten Global Pharmaceutical Markets, 2008 63
 Table 3.7: BRIC Countries, Percentage of GDP Spent on Healthcare, 2008 63
 Table 3.8: Percentage of GDP Healthcare Spending by Country, 2008 64
 Table 3.9: Top 20 Generic Drugs by Prescriptions, 2008 67
 Table 3.10: Anti-Bacterial Agents Undergoing Clinical Development 68
 Table 3.11 Leading Tuberculosis R&D Candidates 69
 Table 3.12: Pipeline for Repositioned Drugs 69
 Table 4.1: Potential Anti-Bacterial Protein Drug Targets 74
 Table 4.2: In vitro Susceptibility of Staphylococci to New Agents in Development 74
 Table 4.3: Anti-Staphylococcal Vaccines and Immunoglobulins in the Late Stage Pipeline, 2009 75
 Table 4.4: Bacterial Targets of Antibiotics and Resistance Mechanisms 75
 Table 4.5: Guideline Summary for Antibiotic Selection for Skin and Soft Tissue Infections 76
 Table 4.6: Selected Anti-Viral Drugs 84
 Table 4.7: Anti-Retrovirals in Development, 2008 84
 Table 4.8: New Types of HIV Drugs 85
 Table 4.9: Recommended Daily Dosage of Seasonal Influenza Anti-Viral Medications for Treatment and Chemoprophylaxis in the U.S., 2008-2009 86
 Table 4.10: Percentage Drug Resistance for Common Influenza Virus Strains, 2009 87
 Table 4.11: Selected HCV Drugs in Development, 2009 88
 Table 4.12: Therapeutic Agents in Development for Treating Hepatitis B, 2008 89
 Table 4.13: Anti-Fungal Compounds in Late Stage Development 90
 Table 4.14: New Vaccines Licensed, 2005-2010 92
 Table 4.15: Global Top Selling Blockbuster Vaccines, 2008 96
 Table 4.16: Selected Anti-Infective Monoclonal Antibodies in Clinical Development, 2009 96

Table 5.1: FDA-approved Commercial Kits for the Detection of Infectious Agents 98
Table 5.2: Examples of Personalized Medicine in Treatment of Infectious Disease 99
Table 6.1: Competitive Landscape for Anti-Viral Drugs in Development, 2009 103
Table 6.2: Competitive Landscape for Antibiotic Drugs in Development, 2009 103
Table 8.1 Anti-HIV Therapeutics Approved by the FDA 110
Table 9.1: Major Classes of Antibiotics 112
Table 10.1: Major Classes of Anti-Fungals 118
Table 11.1: CCR-5 Receptor Agonists in Development, 2009 125
Table 12.1: Major Pathogens Identified in the Last 30 Years 130
Table 12.2: Emerging and Re-emerging Infectious Diseases and their Geographical Location 133
Table 16.1: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2008 143
Table 16.2: International Regulatory Measures Indicated by the International Forum of Anti-Bacterial Resistance 145
Table A2.1: Anti-HCV Pipeline, 2009 200
Table A3.1: European Sales of Animal Health Antibiotics, 2005-2012 204
Table A3.2: Use of Antibiotics as Growth Promotants 206
Table A4.1: Market Structure for Infectious Disease Diagnostics 210
Table A4.2: Rapid Strep Tests on the Market 211
Table A4.3: Rapid Tests for Chlamydia 213
Table A4.4: Rapid Tests for Gonorrhoea 215
Table A4.5: Burden of Influenza 216
Table A4.6: Global Market Potential for TB Diagnostic Testing, 2000-2010 221
Table A4.7: Global Market for HBV Diagnostic Testing, 2000-2012 224
Table A4.8: U.S. Market for HBV Diagnostic Testing, 2000-2012 224
Table A4.9: Serological Diagnosis of Hepatitis B Virus Infections 226
Table A4.10: Lower Detection Limits of HBV DNA Assays 227
Table A4.11: Type of Test: Lateral Flow 230
Table A4.12: Type of Test: Flow-through 231
Table A4.13: Type of Test: Agglutination 231
Table A4.14: Type of Test: Immunoblot 231
Table A4.15: Global Market for HCV Diagnostic Testing, 2000-2009 234
Table A4.16: Efficiency of Available HCV Screening Tests 235
Table A4.17: Recommendations for Diagnostic Testing for Hepatitis C 237

Ordering

Order Online - <http://www.bioseeker.com/market-research-report/anti-infective-drugs-markets.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioSeeker Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit <http://www.bioseeker.com/market-research-report/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Anti-Infective Drugs Markets**

Web Address: <http://www.bioseeker.com/market-research-report/anti-infective-drugs-markets.html>

Format: PDF

Price: 11100 EUR (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 EUR.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS
MWST / IVA / FPA number:

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
 - Master Card
 - Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

- Pay by check:**

Please post the check, accompanied by this form, to:
BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:
Marketing Code: _____

Please supply purchase order number if needed: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioSeeker Group you are agreeing to our Terms and Conditions at <http://www.bioseeker.com/market-research-report/biomarket-group-full-terms-and-conditions/>

Please fax this form to: +46-8-56849191